Scott Platshon is a Partner at EcoR1 Capital, a San Francisco-based venture firm focused on biotechnology. See sector focus and contact routes.
Scott Platshon is a Partner at EcoR1 Capital, a San Francisco-based venture firm focused on biotechnology, where he has worked since October 2015 after starting as a Principal in 2017 and advancing to Partner in December 2020. His investment thesis centers on fundamental, value-oriented opportunities in the biotechnology sector, particularly in oncology and multifunctional biotherapeutics, with a geographic focus on companies accessible through EcoR1’s San Francisco base. While specific check sizes and lead/follow behavior are not publicly disclosed, Platshon actively serves on boards and as a board observer for multiple portfolio companies, indicating deep operational involvement. Notable portfolio companies include Zymeworks (where he serves as Acting Chief Investment Officer and previously on the board), Kumquat Biosciences (board member since 2021), Ajax Therapeutics (board member since 2021), and Terremoto Biosciences (former board director). Platshon holds a B.S. in Bioengineering from Stanford University and has no publicly available distinctive point of view or published writing beyond his corporate roles and board memberships.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in San Francisco.
Investors like Scott Platshon · Full investor directory · Investor access · Company funding database